P. Savage

发表

Effects of metalloprotease inhibitors on smooth muscle endothelin-converting enzyme activity.

A. Jeng, J. Balwierczak, P. Kukkola, 1995, Biochemical pharmacology.

Upregulation of endothelin-1 binding in tissues of salt-loaded stroke-prone spontaneously hypertensive rats.

A. Jeng, P. Savage, 2002, Canadian journal of physiology and pharmacology.

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

A. Younes, S. Harrison, R. Bugarini, 2014, Leukemia & lymphoma.

Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11

A. Jeng, P. Savage, M. WallaceEli, 1997 .

A comparison of the binding of endothelin to various tissues from spontaneously hypertensive and Wistar-Kyoto rats

A. Jeng, P. Savage, Shiling Hu, 1991, Neurochemistry International.

Expression, purification and characterization of the monomeric and dimeric forms of soluble bovine endothelin converting enzyme-1a.

M. Yanagisawa, B. Bowen, A. Jeng, 2002, Clinical science.

Differential Structure‐Activity Relationships of Phosphoramidon Analogues for Inhibition of Three Metalloproteases: Endothelin‐Converting Enzyme, Neutral Endopeptidase, and Angiotensin‐Converting Enzyme

A. Jeng, P. Kukkola, P. Savage, 1995, Journal of cardiovascular pharmacology.

Chronic Administration of the Nitric Oxide Synthase Inhibitor, L-NAME, Increases Circulating Endothelin Levels in Guinea Pigs

A. Jeng, D. Clark, U. Munshi, 1995 .

Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.

A. Jeng, P. Savage, E. Wallace, 1998, Journal of medicinal chemistry.

Dual effects of endothelin-1 on neurite outgrowth induced by 12-O-tetradecanoylphorbol-13-acetate

A. Jeng, P. Savage, L. Hsu, 1992, Neuroscience Letters.

Isoindolines: a new series of potent and selective endothelin-A receptor antagonists.

A. Jeng, P. Kukkola, P. Savage, 2001, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.

K. Chan, Y. Satoh, A. Jeng, 2001, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.

D. Hoyer, A. Jeng, P. Savage, 2000, Bioorganic & medicinal chemistry letters.

Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.

D. Hoyer, A. Jeng, P. Savage, 2002, Clinical science.

CGS 35601 and its Orally Active Prodrug CGS 37808 as Triple Inhibitors of Endothelin-converting Enzyme-1, Neutral Endopeptidase 24.11, and Angiotensin-converting Enzyme

A. Jeng, P. Savage, A. Trapani, 2004, Journal of cardiovascular pharmacology.

Characterization of a Potent and Selective Endothelin‐B Receptor Antagonist, IRL 2500

A. Jeng, J. Balwierczak, P. Savage, 1995, Journal of cardiovascular pharmacology.

Activation of BKCa channel via endothelin ETA receptors in porcine coronary artery smooth muscle cells

A. Jeng, P. Savage, Shiling Hu, 1997 .

Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.

D. Hoyer, Y. Satoh, D. Hoyer, 2000, Journal of medicinal chemistry.

ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells.

M. Cleary, P. Savage, J. Rubnitz, 1994, Blood.

Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.

G. Ksander, A. Jeng, G M Ksander, 1998, Journal of cardiovascular pharmacology.

Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.

G. Ksander, A. Jeng, Arco Y Jeng, 2002, Canadian journal of physiology and pharmacology.

Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects.

V. Fischer, L. Alland, M. Kagan, 2005 .

Optimization of retro-thiorphan for inhibition of endothelin converting enzyme

A. Jeng, P. Kukkola, P. Savage, 1996 .

Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelin-1.

A. Jeng, R. Lappe, J. Balwierczak, 1993, Biochemistry and molecular biology international.

Identification of a novel aspartyl endothelin converting enzyme in porcine aortic endothelial cells.

A. Soriano, P. Savage, S. S. Shetty, 1993, Biochemistry and molecular biology international.

Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT).

A. Younes, R. Bugarini, D. Ritchie, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor.

A. Jeng, S. De Lombaert, P. Savage, 1998, Journal of cardiovascular pharmacology.